MX2021004709A - Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1. - Google Patents

Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1.

Info

Publication number
MX2021004709A
MX2021004709A MX2021004709A MX2021004709A MX2021004709A MX 2021004709 A MX2021004709 A MX 2021004709A MX 2021004709 A MX2021004709 A MX 2021004709A MX 2021004709 A MX2021004709 A MX 2021004709A MX 2021004709 A MX2021004709 A MX 2021004709A
Authority
MX
Mexico
Prior art keywords
treating cancer
signaling inhibitor
medicament
cancer unresponsive
unresponsive
Prior art date
Application number
MX2021004709A
Other languages
English (en)
Spanish (es)
Inventor
Nobuyuki Ishikura
Toshiki Iwai
Masamichi Sugimoto
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2021004709A publication Critical patent/MX2021004709A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2021004709A 2018-10-31 2019-10-17 Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1. MX2021004709A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018206076 2018-10-31
PCT/IB2019/058848 WO2020089722A1 (en) 2018-10-31 2019-10-17 Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor

Publications (1)

Publication Number Publication Date
MX2021004709A true MX2021004709A (es) 2021-06-04

Family

ID=70463563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004709A MX2021004709A (es) 2018-10-31 2019-10-17 Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1.

Country Status (12)

Country Link
US (2) US12577307B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873527A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022509448A (cg-RX-API-DMAC7.html)
KR (1) KR20210084560A (cg-RX-API-DMAC7.html)
CN (1) CN114340679A (cg-RX-API-DMAC7.html)
AU (1) AU2019372239A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008117A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115798A1 (cg-RX-API-DMAC7.html)
IL (1) IL282654A (cg-RX-API-DMAC7.html)
MX (1) MX2021004709A (cg-RX-API-DMAC7.html)
TW (1) TW202031291A (cg-RX-API-DMAC7.html)
WO (1) WO2020089722A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
JP7148037B2 (ja) 2018-12-03 2022-10-05 イミューンオンコ バイオファーマシューティカルズ (シャンハイ) インコーポレイテッド Pd-l1とvegfを標的化する組換えタンパク質
WO2022089377A1 (en) * 2020-10-26 2022-05-05 Taizhou Eoc Pharma Co., Ltd. Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer
WO2023088436A1 (zh) * 2021-11-18 2023-05-25 信达生物制药(苏州)有限公司 抗pd-1抗体和抗vegf-a抗体的药物组合及其使用方法
TW202444368A (zh) * 2023-03-30 2024-11-16 瑞典商米迪維艾克提伯拉公司 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法
KR20260116273A (ko) 2024-09-20 2026-07-28 파라곤 테라퓨틱스, 인크. Pd-1 결합 단백질, vegf 및 pd-1 이중특이적 결합 단백질, 조성물 및 사용 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
DK3858859T3 (da) 2015-07-14 2025-12-15 Bristol Myers Squibb Co Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1)
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
MX2019010295A (es) 2017-03-01 2019-11-21 Genentech Inc Métodos de diagnóstico y terapéuticos para el cáncer.

Also Published As

Publication number Publication date
JP2022509448A (ja) 2022-01-20
TW202031291A (zh) 2020-09-01
WO2020089722A1 (en) 2020-05-07
US20210388090A1 (en) 2021-12-16
US20260176363A1 (en) 2026-06-25
EP3873527A1 (en) 2021-09-08
CA3115798A1 (en) 2020-05-07
KR20210084560A (ko) 2021-07-07
IL282654A (en) 2021-06-30
EP3873527A4 (en) 2022-09-07
US12577307B2 (en) 2026-03-17
CN114340679A (zh) 2022-04-12
BR112021008117A2 (pt) 2021-08-31
JP2025060639A (ja) 2025-04-10
AU2019372239A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
BR112018073328A2 (pt) combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
MX2018016046A (es) Quinazolina y compuestos indol para tratar trastornos medicos.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
MX375194B (es) Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa.
MX383484B (es) Método para tratar el cáncer.
MA39906A (fr) Polythérapies pour le traitement du cancer
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
MX2020003361A (es) Combinacion de un inhibidor parp y un antagonista de union al eje pd-1.
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX390320B (es) Farmaco de combinacion.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX2019013862A (es) Terapia de combinacion.
MX394452B (es) Inhibicion de la actividad de olig2.